Could Cilta-cel Become the BCMA CAR-T of Choice in 2021? ASH Day 3 Legend Investor Event
On the third day of ASH 2020, Legend held an investor event to discuss the recent data presented at ASH 2020 from the Ph1b/2 CARTITUDE-1 study. Below, Celltelligence provides a summary of the call, JNJ’s / Legend’s possible messaging for cilta-cel, and regulatory updates in the US and EU.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.